Article

Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase

2019-08-16

Abstract excerpt

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm constituting approximately 15% of newly diagnosed leukemia in adult patients. Development of tyrosine kinase inhibitors (TKIs) have dramatically improved outcomes in patients with chronic CML in chronic phase. However, adverse drug events (ADEs) associated with TKI therapy have influenced drug adherence, resulting in adverse clinical outcomes and a de...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f9c5a989-9ac1-53d1-93c3-c2e2b3cb6036
DOI: 10.20944/preprints201908.0177.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic PhaseDOI 10.20944/preprints201908.0177.v1Read

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.Semantic proximity Read

A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.Semantic proximity Read

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Semantic proximity Read

Beyond Disease Control in Chronic Myeloid Leukemia: Real-World Quality of Life Across TKIs and Treatment-Free RemissionSemantic proximity Read

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.Semantic proximity Read

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.Semantic proximity Read

Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.Semantic proximity Read

[Treatment of two chronic myeloid leukemia patients with V299L mutation by using nilotinib].Semantic proximity Read

Influence of cytochrome P450 and glutathione S transferase polymorphisms on response to nilotinib therapy among chronic myeloidleukemia patients from Pakistan.Semantic proximity Read

INCIDENCE AND ASSOCIATED FACTORS WITH THE CHANGE FREE TIME BETWEEN THE BRANDED OR GENERIC IMATINIB IN NAIVE PATIENTS WITH CHRONIC MYELOID LEUKEMIASemantic proximity Read

Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.Semantic proximity Read

[Clinical efficacy of switching to 2nd generation of tyrosine kinase inhibitor on CML patients at poor responses to imatinib].Semantic proximity Read